article thumbnail

ARRS: How to manage the side effects of radiopharmaceuticals

AuntMinnie

Three clinical issues that may arise with theranostics treatments will require special provisions, including spot imaging, according to insights shared during the 124th annual meeting of the American Roentgen Ray Society (ARRS) in Boston. Extravasations Extravasations, in particular, are of interest to the U.S.

article thumbnail

University Hospitals Cleveland, Siemens Healthineers in New Alliance to Improve Oncology, Cardiovascular and Neurovascular Care for Patients

Imaging Technology

milla1cf Tue, 05/14/2024 - 12:45 May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on their 40-year history of clinical and research collaboration. Because there is no “typical” hospital or laboratory and many variables exist (e.g.,

Hospital 103
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

Imaging Technology

milla1cf Wed, 02/21/2024 - 18:58 February 21, 2024 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, is pleased to share the publication of promising early clinical data with 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 81
article thumbnail

Blue Earth highlights early lutetium-177 prostate cancer clinical results

AuntMinnie

Blue Earth Therapeutics is highlighting early clinical results from a German trial investigating the use of a lutetium-177 (Lu-177)-labeled prostate specific antigen (PSMA) radiopharmaceutical. A phase I and II clinical trial assessing the safety, tolerability, dosimetry, and antitumor activity of Lu-177 rhPSMA-10.1

Clinic 40
article thumbnail

SNMMI: Lu-177 PSMA-617 shines for taxane-naive prostate cancer

AuntMinnie

TORONTO – The radiopharmaceutical Pluvicto improves progression-free survival in patients with metastatic prostate cancer who haven’t undergone taxane therapy, according to research presented at the SNMMI meeting. Oliver Sartor, MD The study, which was awarded SNMMI’s Abstract of the Year award, shared data from the phase III PSMAfore trial.

article thumbnail

SNMMI Elects Heather Jacene, MD, as Vice President-Elect at 2024 Annual Meeting

Imaging Technology

She will also raise awareness of nuclear medicine’s value to clinical colleagues and patients and will be laser-focused on breaking down barriers to radiopharmaceutical availability, reimbursement, affordability, and funding. An active SNMMI member, Jacene has been involved in many aspects of the organization.

article thumbnail

RefleXion highlights new CMS payment rate, codes for Scintix system

AuntMinnie

These are created by injecting the patient with a radiopharmaceutical to deliver a radiation dose that targets the cancer itself. CMS created two new reimbursement codes for use in the hospital outpatient setting, effective January 1, to describe Scintix therapy.